Geraldine OSullivan Coyne
Overview
Explore the profile of Geraldine OSullivan Coyne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gross A, OSullivan Coyne G, Dombi E, Tibery C, Herrick W, Martin S, et al.
Nat Med
. 2025 Jan;
31(1):105-115.
PMID: 39762421
The MEK inhibitor selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). To evaluate whether similar outcomes were possible...
2.
Jha A, Patel M, Ling A, Shah R, Chen C, Millo C, et al.
Eur Radiol
. 2024 Apr;
34(10):6488-6498.
PMID: 38625612
Objective: To compare the diagnostic performance of [Ga]DOTATATE PET/CT, [F]FDG PET/CT, MRI of the spine, and whole-body CT and MRI for the detection of pheochromocytoma/paraganglioma (PPGL)-related spinal bone metastases. Materials...
3.
Redman J, OSullivan Coyne G, Reed C, Madan R, Strauss J, Steinberg S, et al.
Oncologist
. 2023 Jun;
28(9):823-e804.
PMID: 37310790
Background: Metastatic colorectal cancer (mCRC) is incurable, and median overall survival is less than 2½ years. Although monoclonal antibodies that block PD-1/PD-L1 interactions are active in microsatellite unstable/mismatch repair deficient...
4.
Nguyen J, Takebe N, Kummar S, Razak A, Chawla S, George S, et al.
Clin Cancer Res
. 2022 Oct;
29(7):1200-1208.
PMID: 36302173
Purpose: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor with few treatment options. We designed a phase II randomized trial to determine the activity and tolerability of...
5.
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
OSullivan Coyne G, Karlovich C, Wilsker D, Voth A, Parchment R, Chen A, et al.
Onco Targets Ther
. 2022 Mar;
15:165-180.
PMID: 35237050
Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline mutations, but as evidence and approvals for their use in a wider range of...
6.
OSullivan Coyne G, Kummar S, Hu J, Ganjoo K, Chow W, Do K, et al.
Clin Cancer Res
. 2021 Oct;
28(2):279-288.
PMID: 34716194
Purpose: Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated...
7.
OSullivan Coyne G, Naqash A, Sankaran H, Chen A
Curr Probl Cancer
. 2021 Jul;
45(4):100775.
PMID: 34284873
Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue sarcoma subtypes, an infrequent subtype within the already rare category of human malignancy of sarcoma. In this...
8.
Chen A, Kummar S, Moore N, Rubinstein L, Zhao Y, Williams P, et al.
JCO Precis Oncol
. 2021 Apr;
5.
PMID: 33928209
Materials And Methods: Adult patients with an actionable mutation of interest were randomly assigned 2:1 to receive either (1) a study regimen identified to target the aberrant pathway found in...
9.
Takebe N, Naqash A, OSullivan Coyne G, Kummar S, Do K, Bruns A, et al.
Clin Cancer Res
. 2021 Apr;
27(14):3834-3844.
PMID: 33863809
Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose...
10.
Takebe N, OSullivan Coyne G, Kummar S, Collins J, Reid J, Piekarz R, et al.
Oncotarget
. 2021 Mar;
12(4):268-277.
PMID: 33659039
Background: Differential responses to tamoxifen may be due to inter-patient variability in tamoxifen metabolism into pharmacologically active Z-endoxifen. Z-endoxifen administration was anticipated to bypass these variations, increasing active drug levels,...